Targeting MEK is Effective Chemoprevention of Hepatocellular Carcinoma in TGF-α-Transgenic Mice

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of Gastrointestinal Surgery

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11605-007-0396-4
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models

  2008cited by this paper
• Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration

  2007cited by this paper
• Tamoxifen is not effective in good prognosis patients with hepatocellular carcinoma

  2006cited by this paper
• BRAF mutation predicts sensitivity to MEK inhibition

  2006cited by this paper
• Hepatitis B virus infection: epidemiology and vaccination.

  2006cited by this paper
• Prometheus' challenge: molecular, cellular and systemic aspects of liver regeneration.

  2006cited by this paper
• Chemoprevention of spontaneous development of hepatocellular carcinomas in fatty liver Shionogi mice by a cyclooxygenase‐2 inhibitor

  2006cited by this paper
• Hepatitis C virus core protein promotes proliferation of human hepatoma cells through enhancement of transforming growth factor alpha expression via activation of nuclear factor-kappaB.

  2006cited by this paper
• Prevention of hepatocellular carcinoma recurrence with alpha‐interferon after liver resection in HCV cirrhosis

  2006cited by this paper
• Hepatitis C virus core protein promotes proliferation of human hepatoma cells through enhancement of transforming growth factor α expression via activation of nuclear factor-κB

  2006cited by this paper
• Erk Associates with and Primes GSK-3β for Its Inactivation Resulting in Upregulation of β-Catenin

  2005cited by this paper
• Use of tamoxifen in advanced‐stage hepatocellular carcinoma

  2005cited by this paper
• Molecular Mechanisms of Hepatocarcinogenesis in Transgenic Mouse Models of Liver Cancer

  2005cited by this paper
• Prevention of Rat Hepatocarcinogenesis by Acyclic Retinoid Is Accompanied by Reduction in Emergence of Both TGF-α-Expressing Oval-Like Cells and Activated Hepatic Stellate Cells

  2005cited by this paper
• Prevention of Hepatocellular Carcinoma

  2005cited by this paper
• Chemoprevention of hepatocellular carcinoma: use of tamoxifen in an animal model of hepatocarcinogenesis.

  2005cited by this paper
• Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin.

  2005cited by this paper
• Disruption of beta-catenin pathway or genomic instability define two distinct categories of liver cancer in transgenic mice.

  2004influential reference
• Primary liver cancer: worldwide incidence and trends.

  2004cited by this paper
• Targeting the mitogen-activated protein kinase cascade to treat cancer

  2004cited by this paper
• Significance of Hepatic Preneoplasia in Risk Identification and Early Detection of Neoplasia *

  2003cited by this paper
• Interferon therapy as chemoprevention of hepatocarcinogenesis in patients with chronic hepatitis C.

  2003cited by this paper
• Significance of hepatic preneoplasia for cancer chemoprevention.

  2001cited by this paper
• Proliferating cell nuclear antigen and Ki-67 labeling in hepatocellular nodules: a comparative study.

  1999influential reference
• Synergy between transforming growth factor alpha and hepatitis B virus surface antigen in hepatocellular proliferation and carcinogenesis.

  1997cited by this paper
• Human hepatic preneoplasia: phenotypes and proliferation kinetics of foci and nodules of altered hepatocytes and their relationship to liver cell dysplasia

  1997influential reference
• Increased MAPK expression and activity in primary human hepatocellular carcinoma.

  1997influential reference
• Rapid development of hepatic tumors in transforming growth factor alpha transgenic mice associated with increased cell proliferation in precancerous hepatocellular lesions initiated by N-nitrosodiethylamine and promoted by phenobarbital.

  1994cited by this paper
• Transforming growth factor alpha dramatically enhances oncogene-induced carcinogenesis in transgenic mouse pancreas and liver

  1993influential reference
• Development of liver tumors in transforming growth factor alpha transgenic mice.

  1992cited by this paper
• Development of Liver Tumors in Transforming Growth Factor α Transgenic Mice

  1992cited by this paper
• Significance of Sequential Cellular Changes Inside and Outside Foci of Altered Hepatocytes During Hepatocarcinogenesis∗

  1989influential reference
• Hepatocellular carcinoma.

  1986cited by this paper
• Primary liver cancer

  1985cited by this paper
• A morphologic classification of proliferative and neoplastic hepatic lesions in mice.

  1979cited by this paper

• In Silicon Approach for Discovery of Chemopreventive Agents

  2017cites this paper
• A PTEN inhibitor displays preclinical activity against hepatocarcinoma cells

  2016cites this paper
• Mammalian models of chemically induced primary malignancies exploitable for imaging-based preclinical theragnostic research.

  2015cites this paper
• Hepatocellular carcinoma: systemic therapies and future perspectives

  2014cites this paper
• [Current status of molecular targeted therapies in hepatocellular carcinoma].

  2013cites this paper
• Targeted therapy for hepatocellular carcinoma: novel agents on the horizon

  2012cites this paper
• Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance

  2012cites this paper
• Erk1 and Erk2 in hematopoiesis, mast cell function, and the management of Nf1-associated leukemia and tumors

  2012cites this paper
• Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health

  2011cites this paper
• Targeting key signalling pathways in oesophageal adenocarcinoma: a reality for personalised medicine?

  2011cites this paper
• Molecularly targeted therapy in hepatocellular carcinoma.

  2010cites this paper
• Synergistic growth inhibition of anaplastic large cell lymphoma cells by combining cellular ALK gene silencing and a low dose of the kinase inhibitor U0126

  2010cites this paper
• Tyrosine kinase inhibitors to treat liver cancer

  2010cites this paper
• MEK Inhibitor PD 0325901 Significantly Reduces the Growth of Papillary Thyroid Carcinoma Cells In vitro and In vivo

  2010cites this paper
• Activation of multiple signaling pathways causes developmental defects in mice with a Noonan syndrome–associated Sos1 mutation.

  2010cites this paper
• MEK Inhibitor PD0325901 Significantly Reduces the Growth of Papillary Thyroid Carcinoma Cells In vitro and In vivo

  2010cites this paper
• Emerging MEK inhibitors

  2010cites this paper
• Targeting mitogen‐activated protein kinase kinase with the inhibitor PD0325901 decreases hepatocellular carcinoma growth in vitro and in mouse model systems

  2010cites this paper
• Targeted therapy of hepatocellular cancer

  2010cites this paper
• Modeling pro-death signaling pathways in cancer hepatocytes using multi-combinatorial treatments of inhibitors and stimuli

  2008cites this paper